Browsing Tag
Medicare
18 posts
FDA approves Lilly’s Foundayo as second oral GLP-1 weight loss pill, challenging Novo Nordisk’s head start
FDA approves Eli Lilly's Foundayo (orforglipron), the second oral GLP-1 obesity pill with no food restrictions. What this means for LLY investors and patients. Read more.
How FDA-aligned endpoints position inFoods IBS alongside drug therapies
Biomerica, Inc. aligns inFoods IBS with FDA drug endpoints and secures Medicare pricing. See what this means for IBS competitors and investors.
CMS LCD withdrawal gives Kerecis fish-skin platform a strategic edge in outpatient wound care reimbursement
CMS pulled back LCD restrictions on wound grafts. Find out how Kerecis' fish-skin platform is gaining a strategic edge as reimbursement reforms unfold.
Inside the CVS whistleblower case that led to a $37.76m pharmacy fine
CVS Health agrees to pay $37.76M to settle insulin billing fraud claims. Find out what this means for drug pricing and pharmacy compliance in 2025.
Will payers embrace premium weight loss? Inside the reimbursement risks of next-gen GLP-1s
As GLP‑1 weight‑loss drugs climb toward blockbuster status, insurers and payers face tough choices on coverage. Can premium weight‑loss therapies become mainstream?
King Risk Partners expands health insurance presence with Ricky Credille Insurance acquisition
King Risk Partners strengthens its Medicare and health insurance services with the acquisition of Ricky Credille Insurance. Find out more.
Medtronic’s Symplicity Spyral RDN catheter secures CMS approval for boosted Medicare access
The US Centers for Medicare & Medicaid Services (CMS) has granted Medtronic plc, a global healthcare technology leader,…
Centene’s Buckeye Health Plan wins Ohio Medicaid contract for dual-eligible healthcare
Buckeye Health Plan, a subsidiary of Centene Corporation (NYSE: CNC), has been awarded a significant contract by the…
SelectQuote shares plunge after dismal earnings report and gloomy forecast
SelectQuote, Inc., a publicly traded insurance distribution company, has seen a dramatic collapse in its share price following…
GRAIL’s new REACH study of Galleri MCED test set to change future of cancer detection for seniors – Find out how
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company renowned for its mission to detect cancer early when it can…